CILFA

What CILFA does

CILFA (Cámara Industrial de Laboratorios Farmacéuticos Argentinos) is an Argentine industrial chamber founded in June 1964 that represents pharmaceutical laboratories of national capital. It currently counts over 40 member laboratories that collectively account for approximately 90% of the Argentine pharmaceutical market by volume and 60% by value, with combined production capacity of roughly 690 million units per year and an industry employment footprint of about 43,000 direct and 120,000 indirect workers. The chamber's functional role is collective representation and advocacy rather than product commercialization: it defends members' interests before Argentine regulators (notably ANMAT), negotiates policy on intellectual property and trade, participates in international bodies (ALIFAR, IGBA, WHO, WIPO, WTO), and produces economic studies and monthly industry reports (CILFA al día).

The business model is a membership-based trade association: revenue is generated through subscription/recurring membership fees paid by member laboratories, supplemented by sponsored events, seminars, and economic publications. Pricing is not publicly disclosed and is negotiated individually with member labs. CILFA employs 11–50 staff, headed by an Executive Director (Eduardo Franciosi) and governed by a Comisión Directiva whose seats are held by senior executives of member companies (President Jorge Belluzzo of Adium Argentina, VPs from Roemmers, Elea Phoenix, and Bagó, and board members from Richmond, Casasco, Gador, Baliarda, Biosidus, and others). Operations are headquartered at Av. del Libertador 602, Piso 6, Buenos Aires.

CILFA does not develop or sell technology products and has no disclosed AI/ML, API, or SaaS offering; its service portfolio is institutional (advocacy, training, press releases, regulatory guidance, joint initiatives such as Sinergium Biotech). The 2024 admission to full membership in IGBA marked its first international structural expansion beyond the existing ALIFAR/WHO/WIPO/WTO footprint, making it the first Latin American association to hold that IGBA status.

Name

CILFA

Legal name

Cámara Industrial de Laboratorios Farmacéuticos Argentinos

Website

https://cilfa.org.ar

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

11–50 employees

Short description

CILFA is the Argentine industrial chamber founded in 1964 that represents over 40 nationally-capitalized pharmaceutical laboratories, collectively covering ~90% of the domestic pharma market by volume. It delivers advocacy, regulatory representation, economic research, and international liaison (ALIFAR, IGBA, WHO, WIPO, WTO) on a membership-fee model.

Ownership category

akta.pro rank

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Membership Fees: As a trade association, CILFA generates revenue through membership fees paid by pharmaceutical laboratories. These fees fund the chamber's activities including advocacy, representation, economic studies, training programs, and industry events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CILFA is an industry chamber (trade association) that represents and advocates for Argentine pharmaceutical laboratories of national capital. It provides regulatory affairs support, monthly economic reports, sector studies, press releases, intellectual property advisory, training programs, and international representation through memberships in ALIFAR, IGBA, UIA, WHO, WIPO, and WTO.

Product overview

CILFA (Cámara Industrial de Laboratorios Farmacéuticos Argentinos) is an industry association representing Argentine national pharmaceutical laboratories. It does not offer technology products but provides institutional services including monthly economic reports (CILFA al día), sector studies, regulatory guidance, press releases, events and seminars, and policy advocacy for the national pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Products and services

• CILFA al día (Monthly Economic Reports) Monthly economic reports published as PDFs covering Argentine pharmaceutical market data, statistics, and analysis for member laboratories.
• Economic Sector Studies In-depth sector studies on the Argentine pharmaceutical industry, produced for member laboratories and industry stakeholders.
• Sanitary Regulations and Regulatory Affairs Support Regulatory affairs services and coordination with Argentine health authority ANMAT, including GMP/GDP guidance and technical sheets for member laboratories.
• Industry Events and Seminars Seminars, conferences, and industry events organized for member laboratories and the broader Argentine pharmaceutical industry.
• Intellectual Property Advisory Intellectual property advisory and representation of member laboratories' interests before international IP bodies such as WIPO.
• Press Releases and Press Communications Press releases issued by CILFA communicating industry positions, regulatory developments, and chamber news.
• Sector Information and Coyuntura Reports Resources covering sector information, technical sheets, and situational reports (reportes de coyuntura) for member laboratories.

Named customers39 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and minor.

• ALIFAR (Asociación Latinoamericana de Industrias Farmacéuticas)coreStrategic or Co-development PartnerALIFAR is the Latin American Federation of Pharmaceutical Industries. CILFA participates as the Argentine member, contributing to regional pharmaceutical industry advocacy and policy coordination across Latin America.
• IGBA (International Generic and Biosimilar Medicines Association)coreStrategic or Co-development PartnerCILFA achieved full membership status in the IGBA, providing access to international networks for generic and biosimilar medicines, facilitating knowledge sharing and global industry representation.
• UIA (Unión Industrial Argentina)coreStrategic or Co-development PartnerUIA is Argentina's main industrial confederation. CILFA serves as the specialized pharmaceutical sector chamber within this broader industrial federation.
• OMS (Organización Mundial de la Salud) / WHOcoreStrategic or Co-development PartnerCILFA maintains official relationships with the World Health Organization, participating in international health policy discussions relevant to the pharmaceutical industry.
• OMPI (Organización Mundial de la Propiedad Intelectual) / WIPOcoreStrategic or Co-development PartnerCILFA has established relationships with the World Intellectual Property Organization for intellectual property matters affecting the pharmaceutical sector.
• OMC (Organización Mundial del Comercio) / WTOcoreStrategic or Co-development PartnerCILFA maintains relationships with the World Trade Organization for trade policy and commercial matters affecting pharmaceutical imports and exports.
• Sinergium BiotechminorStrategic or Co-development PartnerSinergium Biotech is a joint venture involving member laboratories, focused on biotech pharmaceutical development and production in Argentina.
• CICYPminorStrategic or Co-development PartnerCICYP (Centro de Información y Comunicación para la Producción) is a local industry information and communication organization that CILFA collaborates with.
• FIEL (Fundación de Investigaciones Económicas Latinoamericanas)minorStrategic or Co-development PartnerFIEL is the Foundation for Latin American Economic Research. CILFA collaborates with FIEL for economic research and analysis related to the pharmaceutical industry.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• JPMA (Japan Pharmaceutical Manufacturers Association): Japanese pharma industry association. Functions as a national pharma chamber with international policy engagement, comparable in mandate to CILFA but with substantially larger membership and budget.
• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations): Global pharma industry federation that interacts directly with WHO. Comparable to CILFA as an industry-chamber peer operating at international level on health policy, IP, and trade matters affecting pharmaceutical manufacturers.
• ABPI (Association of the British Pharmaceutical Industry): UK pharma industry trade association. National-level pharma chamber analogous to CILFA but operating from a mature, developed-market regulatory context; useful as a governance/membership-model comparable.
• FIFARMA (Federación Latinoamericana de la Industria Farmacéutica): Latin American pharma industry federation representing a broader membership base including both national and multinational producers. Comparable to CILFA as a regional pharma-industry chamber, though with a wider membership profile.
• PhRMA (Pharmaceutical Research and Manufacturers of America): Major US pharma industry trade association. Operates at far greater scale than CILFA in the same fundamental role of representing pharma manufacturers before government and shaping R&D, IP, and pricing policy — a clear broad-incumbent industry-level peer.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): European pharma industry federation. Same industry-chamber model as CILFA, executed at multi-country European scale; a relevant global-level comparable on governance, advocacy, and IP/trade-policy engagement.

Regional players

• CANIFARMA (Cámara Nacional de la Industria Farmacéutica, Mexico): Mexican national pharma industry chamber. Direct regional comparable to CILFA in role and structure, but operating in Mexico rather than Argentina — a useful neighboring-country peer that competes within ALIFAR for regional influence.

Direct peers

• IGBA (International Generic and Biosimilar Medicines Association): Global association of generic and biosimilar medicine manufacturers. CILFA achieved full IGBA membership in 2024 — the first Latin American association to do so — so IGBA is the international peer most tightly aligned with CILFA's focus on national/generic/biosimilar producers.
• ALIFAR (Asociación Latinoamericana de Industrias Farmacéuticas): Latin American federation of national pharma industry chambers. CILFA was a promoter of ALIFAR's creation and acts as the Argentine member, making ALIFAR the immediate regional-level peer sharing CILFA's mandate of defending national-capital pharmaceutical producers.
• CAEME (Cámara Argentina de Especialidades Medicinales): Argentine pharma trade chamber that represents the multinational/large foreign-capital laboratories operating in Argentina. CAEME and CILFA sit on the same Argentine pharma advocacy bench and compete for the political voice of the broader industry, making CAEME the most directly comparable peer to CILFA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cilfa-c-mara-industrial-de-laboratorios-farmac-uticos-argentinos

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CILFA